Book a Demo
Back to All Playbooks

Script collection

Biopharma & FDA Affairs conversation scripts

10 spoken scripts and techniques for Biopharma & FDA Affairs conversations, collected on one page. Practice them out loud in Dehurdle.

These scripts are for practicing conversations. They are not medical, legal, or financial advice. Follow your organization's policies and the guidance of qualified professionals.

Dehurdle editorial team
Published · Updated

Answering FDA Form 483 Inspection Observations with Immediate Corrective Action

Receiving FDA 483 inspection observations can delay multi-billion dollar drug approvals. How Regulatory Affairs leaders deliver CAPA commitments in the closeout meeting.

The FDA Closeout Meeting Response

Recommended script
"We acknowledge the investigator's observation regarding environmental monitoring in Cleanroom B. We have initiated an immediate Corrective and Preventive Action (CAPA) plan, re-calibrated the differential pressure sensors, and will submit complete validation documentation within 15 business days."

Defending Biologic Drug Approval Endpoints in Public FDA Advisory Hearings

FDA Advisory Committee (AdCom) panel votes can heavily influence approval decisions. How Chief Medical Officers present Progression-Free Survival (PFS) endpoints under intense panel cross-examination.

The Statistical Risk-Benefit Presentation

Recommended script
What to say to the panel: "The clinical benefit is demonstrated by a statistically robust 4.8-month improvement in median Progression-Free Survival with a Hazard Ratio of 0.62 (p < 0.001). In a patient population with zero approved second-line therapies, this efficacy endpoint represents a transformative therapeutic advance with a manageable, non-cumulative toxicity profile."

Structuring Milestone Payouts in Phase 3 Oncology Drug Licensing Deals

Biotech founders often agree to back-weighted milestone schedules that leave them cash-starved during costly Phase 3 clinical trials. How to negotiate upfront developmental tranches.

The Developmental Milestone Tranche Script

Recommended script
"To keep our Phase 3 trial enrollment on its 18-month timeline, we require a $45M upfront licensing payment and $30M upon First Patient Dosed. Back-weighting milestones solely to NDA approval forces unnecessary dilution and risks study pacing."

Convincing FDA Medical Reviewers to Lift a Clinical Hold on Gene Therapy Trials

When the FDA places a clinical trial on hold following a Serious Adverse Event (SAE), getting the trial resumed requires presenting rigorous vector biodistribution and toxicology data.

The Clinical Hold Resolution Presentation

Recommended script
"Our preclinical toxicology reassessment indicates the immune response was triggered by viral capsid antibody cross-reactivity at the highest dose tier. We have amended our investigational protocol to include mandatory baseline antibody screening and a 50% dose reduction to widen the safety margin for trial resumption."

Presenting Post-Market Safety Signal Data to European EMA Regulators

When real-world registry data detects a potential drug interaction signal, presenting safety surveillance to European Medicines Agency (EMA) officials requires epidemiologic rigor.

The Pharmacovigilance Risk Management Presentation

Recommended script
"Across 140,000 patient-years of commercial exposure, the observed-to-expected incidence ratio for hepatotoxicity is 1.04, matching background population rates. To ensure proactive physician awareness, we are submitting an updated Summary of Product Characteristics (SmPC) with quarterly liver function monitoring guidelines."

Defending €280k/Year Orphan Drug Pricing to National Health Ministries

Health ministries resist high-cost rare disease treatments. How market access directors prove Quality-Adjusted Life Years (QALY) and offset hospitalization costs.

The Health Economics Offset Defense

Recommended script
"While the annual therapy cost is €280,000, this enzyme replacement therapy is projected to avoid the €450,000 in annual emergency ICU hospitalizations and permanent organ damage previously suffered by each patient, generating a net lifetime saving of €1.2M per treated individual for the national health budget."

Disclosing Bioreactor Contamination to Quality Assurance Oversight Boards

When a 2,000-liter monoclonal antibody batch fails sterility testing, trying to salvage bad lots can create criminal liability. The transparent lot quarantine protocol.

The Immediate Batch Quarantine Script

Recommended script
"Lot #802 exhibited a positive endotoxin test at 72 hours of fermentation. In accordance with cGMP standards, the entire 2,000L batch has been placed under quarantine isolation and rejected. We have initiated clean-in-place steam sterilization across all harvest lines and scheduled a replacement run for Monday."

Negotiating Dedicated Bioreactor Capacity with Global CDMO Manufacturers

CDMO viral vector capacity is constrained globally. How clinical-stage biotechs secure guaranteed manufacturing slots without punitive take-or-pay penalties.

The CDMO Capacity Reservation Script

Recommended script
"We are reserving two 500L viral vector bioreactor suites for Q3 clinical manufacturing. In exchange for a 2-year rolling production commitment with a $2M deposit, we require a flexible 60-day slot deferral window without take-or-pay penalties if clinical trial patient dosing experiences schedule shifts."

Aligning with Academic Medical Centers on Data Rights and Authorship

Academic researchers often demand exclusive publication rights while pharma sponsors need raw clinical trial data for FDA submissions. The collaborative data governance agreement.

The Collaborative Data Governance Script

Recommended script
"We honor the academic investigator's right to independent peer-reviewed publication. To satisfy FDA regulatory filing requirements, our agreement grants the university complete academic publication freedom following a 60-day patent review window, while providing our clinical team real-time access to raw electronic CRF data."
Spoken practice

Practice out loud before the real conversation

Pick one script from this page and say it out loud in Dehurdle. The free speech check shows your speaking pace and how many filler words you use.

Try the Free Speech CheckBook a Demo

More playbooks

10 scripts

Architecture & Construction conversation scripts

10 spoken scripts and techniques for Architecture & Construction conversations, collected on one page. Practice them out loud in Dehurdle.

Read Scripts
10 scripts

Private Equity & Value Creation conversation scripts

10 spoken scripts and techniques for Private Equity & Value Creation conversations, collected on one page. Practice them out loud in Dehurdle.

Read Scripts